

DATE:	8 December 2025
TO:	All Hematologists and Pathologists in Alberta
FROM:	Molecular Pathology Program, Alberta Precision Laboratories
RE:	JAK2 V617F Test Delays

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Provincial JAK2 V617F testing had experienced delayed turnaround times (TAT) over the next several weeks due to a reagent shortage from the vendor. This reagent shortage has been resolved and routine testing has been resumed

Background

- JAK2 V617F targeted testing is performed in Calgary and Edmonton was delayed due to commercial kit manufacturing shortages
- Samples were classified as high priority based on probability of positivity and were tested using the limited supply of available reagent, whereas
 - Low probability of positivity cases were deprioritized and held until reagent became available
- Reagent shortages have now been resolved and all backlog cases are being tested expeditiously.

How this will impact you

- All backlog tests will be performed and reported in EPIC on or before December 5, 2028

Action Required

- **Hematologists and Pathologists:** Be aware that JAK2 V617F results for any delayed cases will be available in EPIC on or before December 5, 2025. Please note that depending on the individual's clinical practice, there may be a significant number of results available for review.

Effective **December 2, 2025**

Questions/Concerns

- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North cheryl.mather@albertaprecisionlabs.ca
- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program
Adrian.box@albertaprecisionlabs.ca

Approved by

- Dr. Adrian Box, Provincial Medical/Scientific Director, Molecular Pathology Program
- Christine Franz, Manager - Genetics & Genomics/Molecular Pathology -South
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories